Nykode Therapeutics ASA
The answer first
Does Nykode Therapeutics beat the market?
No, Nykode Therapeutics has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 10% of Nordic stocks
- Quality34
- Value13
- Trend37
No. 163 of 195 in healthcare
Max for seven days
Follow Nykode Therapeutics with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Nykode Therapeutics
Your first answer is free, no account needed.
Do you own Nykode Therapeutics, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Nykode Therapeutics and a few more. Free, no card.
Super Stock+44.6%In short
- Nykode Therapeutics has risen 25.0% over the past year, including dividends.
- Overall, Nykode Therapeutics ranks better than 10% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 97.4%. The price is 95.4% below its peak now.
Who owns Nykode Therapeutics? See the major shareholders and their stakes
What do analysts think of Nykode Therapeutics?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 10% of Nordic stocks.
No. 163 of 195 in healthcare
Medium An average company: the accounts are neither especially strong nor weak.
No. 154 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.21
- Asset turnoverSales divided by everything the company owns0.00
- Return on equityProfit divided by equity−28.6%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 126 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity1.1
- P/SPrice divided by sales552.6
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Medium The share price has moved about like most stocks over the last year.
No. 91 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−39.2%
- 6 months−18.5%
- 9 months−26.4%
- 12 months+25.0%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Nykode Therapeutics
6 funds we follow own Nykode Therapeutics. The share is how much of the fund the stock makes up.
- Norway5
- Sweden1
From the funds' latest known holdings.
About Nykode Therapeutics
Nykode Therapeutics ASA is a company in healthcare, listed on Oslo Børs. The share trades in NOK. It has around 59 employees.
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include ABI-SUVA for targeting HPV16+ induced malignancies, with head, and neck cancer as the primary indication is in Phase 2 randomized controlled trial. It also offers VB10.NEO, which is in Phase1b VB-N-02 trial; technology platform, which combines genes with desired properties to make novel compounds by creating a new code. Nykode Therapeutics AS was founded in 2006 and is headquartered in Oslo, Norway.


See the full analysis of Nykode Therapeutics.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card